In the present study, we evaluated the potential anti-tumor effects of licofelone, a novel dual 5-LOX-COX- inhibitor (Fig. 1A), and gefitinib, a known EGFR inhibitor (Fig. 1B), either individually or in combination, by simultaneously modulating multiple targets (COX, 5-LOX, EGFR) using a genetically engineered Kras mouse model (GEM) of pancreatic cancer. This evidence concerns the gene ALOX5 and neoplasm.